Gilead Sciences, Inc. (GILD) Presents At Cantor Global Healthcare Conference 2025 Transcript

Gilead Sciences' CMO Dietmar Berger highlighted the company's robust pipeline and strategic focus across virology, oncology, and inflammation at the Cantor Global Healthcare Conference. In virology, Gilead expects key ARTISTRY-1/2 data for BIC/LEN in HIV, providing regimen optionality, and is progressing a once-annual lenacapavir for PrEP, while addressing a clinical hold on its weekly oral HIV therapy. Oncology is bolstered by Trodelvy's strong ASCENT-03/04 data, positioning it for first-line breast cancer, alongside a broad expansion into lung and endometrial cancers, and Anito-cel's promising CAR-T results for multiple myeloma, targeting a 2026 launch. The company is also investing in next-generation and in-vivo CAR-T platforms. The earlier-stage inflammation portfolio includes a Phase II oral alpha-4-beta-7 for IBD, with Gilead actively building a sustainable commercial presence through internal development and potential external partnerships. This diverse 52-molecule pipeline signals substantial future catalysts and growth potential.

Analysis

Gilead Sciences' strategic narrative, as detailed by its Chief Medical Officer, is centered on leveraging its market-leading virology franchise to fund a significant expansion in oncology and build out a third pillar in inflammation. The company's 52-molecule pipeline provides multiple near- and long-term catalysts. In HIV, upcoming Phase III data from the ARTISTRY-1 and 2 studies for the BIC/LEN combination is positioned not as a replacement for the standard-of-care Biktarvy, but as a strategic move to offer a two-drug regimen for optionality and to treat patients on complex regimens. While the wholly-owned weekly oral program (WONDERS) faces a 3-to-6-quarter delay due to a clinical hold, this risk is partially mitigated by an ongoing Phase III weekly collaboration with Merck. The oncology portfolio is a key growth driver, propelled by Trodelvy's positive ASCENT-03 and 04 data, which strongly positions the drug for the lucrative first-line triple-negative breast cancer market and supports a broad development program in lung and endometrial cancers. In parallel, the CAR-T asset anito-cel is advancing toward a targeted 2026 launch for multiple myeloma, with upcoming data expected to reinforce its competitive efficacy and favorable safety profile. Gilead's acquisition of Interius signals a proactive strategy to lead in next-generation in-vivo CAR-T technology. The inflammation portfolio is in an earlier stage, but the company explicitly signals its intent to acquire an "anchor asset" to accelerate growth, pointing to future business development as a core part of its strategy.

Key Decisions for Investors

• Investors should monitor a series of near-term catalysts, including the ARTISTRY-1 and 2 data readouts for the BIC/LEN HIV combo later this year and the updated iMMagine-1 data for the CAR-T therapy anito-cel.
• The primary value driver is the oncology franchise; focus on Trodelvy's commercial execution and market share gains as it expands into the first-line breast cancer setting, which significantly increases its addressable market.
• Given the company's explicit statements, it is prudent to watch for business development or M&A activity in the inflammation space, as an "anchor asset" acquisition is a key part of the strategy to build out this third therapeutic pillar.
• Consider the risk profile of the virology pipeline, noting the 3-to-6 quarter delay in derisking the wholly-owned weekly oral HIV program (WONDERS) following its clinical hold.
• Evaluate Gilead's long-term competitive positioning in cell therapy by tracking progress in its next-generation and in-vivo CAR-T platforms, which are designed to preempt potential technological disruption.